Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.37 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437380 | 0.90 | CENPE (0.38) | MAOBCCR3CYP3A4 | |
| SCHEMBL5446606 | 0.89 | WDR5 (0.36) | CCR3EZH2MAPTMEN1KMT2A | |
| SCHEMBL5457538 | 0.88 | MMP10 (0.35) | GPR52MEN1KMT2A | |
| SCHEMBL31060990 | 0.88 | AKR1B1 (0.36) | MAOB | |
| SCHEMBL4479511 | 0.88 | AKR1B1 (0.36) | MAOB | |
| SCHEMBL5438443 | 0.87 | GAA (0.42) | MAPTKMT2A | |
| SCHEMBL4488414 | 0.87 | AKR1B1 (0.35) | MAOB | |
| SCHEMBL5444577 | 0.86 | WDR5 (0.40) | CCR3EZH2MAPT | |
| SCHEMBL5450208 | 0.86 | EGLN1 (0.37) | MAOBMEN1KMT2A | |
| SCHEMBL5452304 | 0.85 | ALDH1A1 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | claimed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | MAOB 3722/4885ADORA2A 3572/4885CCR3 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.